Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead o... (kets innovative proprietary products for...)

Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule

Date:1/26/2009

kets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that the SUmiT clinical trial will produce favorable results, that even if it produces favorable results third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that even succeed at all at obtaining a specific "listed" CPT code from the AMA for Urgent PC treatments.

For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

For Further Information:

Uroplasty, Inc. EVC Group
David Ka
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression

Post Your Comments:

(Date:6/18/2013)... SALT LAKE CITY , June 18, 2013 ... registry-based informatics products for healthcare and life sciences ... U.S. General Services Administration (GSA) IT Schedule 70 ... is now certified to provide innovative IT solutions ... levels. In accordance with this contract, Remedy has ...

(Date:6/18/2013)... 2013 Polymer Technology Systems, Inc. ... Group to integrate the CardioChek ® ... by health systems across the country. The CardioChek ... distributed through Hanson Medical Systems , offers ... LDL cholesterol, triglycerides, and glucose. (Logo: ...

(Date:6/17/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... filed a preliminary prospectus supplement to its effective shelf registration ... filing with securities regulatory authorities in each of the provinces ... public offering of its common shares to raise gross proceeds ... will also grant to the underwriters of the Offering an ...

Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4

[0] Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients [0] Valeant Pharmaceuticals Announces Public Offering Of Common Shares

... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...

... Millennium Research Group (MRG), the global authority ... latest orthopedics research data including information for multiple ... extremity devices. MRG orthopedic biomaterial reports ... and material, hyaluronic acid viscosupplementation treatments by number ...

Cached Medicine Technology:Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2 New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2

Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group

(Date:6/18/2013)... NY (PRWEB) June 18, 2013 ... hip continue to move forward in a multidistrict litigation ... Liebhard LLP reports. According to court records, the ... 17th, at which time the Court also convened a ... technical issues pertinent to the Biomet hip replacement litigation. ...

(Date:6/18/2013)... Medical Center clinical researchers have launched an innovative ... evaluate the ability of a patient,s own stem ... peripheral arterial disease (PAD). , Led by ... University Hospitals Case Medical Center,s Harrington Heart & ... Western Reserve University School of Medicine, the clinical ...

(Date:6/18/2013)... DC (PRWEB) June 18, 2013 The ... Department of State and the U.S. President’s Emergency Plan ... anniversary and celebrate significant new milestones in the global ... State John Kerry announced that as of June 2013, ... to PEPFAR support. Since PEPFAR’s inception in 2003, ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 Today, Zane ... Health Reimbursement Accounts . Zane Benefits, which provides comprehensive ... is the leader in defined contribution and ... Zane Benefits’ website, employees of a company who sets ... have questions about how Health Reimbursement Accounts work. Educating ...

(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...

Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2 Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3 Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3 Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2

[0] Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation [0] UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation [0] One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS [0] Zane Benefits Publishes New Information on Health Reimbursement Accounts [0] Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in new report by MCD Group

... is pleased to announce,the latest release of TMS Enterprise and ... as requested by our customers., Features such as a ... and retire tasks are just a few of the timesaving ... retire tasks allows users to,remove or retire unnecessary tasks from ...

... Diabetes Federation (IDF) BRIDGES translational research grant program will ... for screenings for people at high-risk for getting type ... people to develop a healthy lifestyle. , The National ... Vinh City, Vietnam. Using diabetes risks questionnaires (1) , ...

... to $9.2 Million, CHENGDU, China, May 15 ... TYNP), a manufacturer and,supplier of modernized traditional Chinese ... results for its third quarter ended,March 31, 2008., ... increased 70.9% to approximately,$9.2 million compared to approximately ...

... Gerson Lehrman Group, the world,s,leading marketplace for ... community devoted to providing patients with the,medication information ... provides personalized iGuard Risk Ratings, iGuard Safety Alerts,and ... with other registered,users who also want to get ...

... Global Unified Worklist Supporting ... SEATTLE, May 15 Compressus, leaders in interoperability,of ... of,Seattle, announced today an agreement to implement a ... management systems.,The implementation, which will include eight SeaRad ...

... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...

Four Rivers Software Systems Delivers TMS Enterprise 2008.3.4 International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions Compressus Announces Seattle Radiologists Interoperability Implementation Treat Your Patients' Pain Effectively

Length-9 (229 mm) Tapered retractor blades....

Pattie Tray...

... for the retraction of nerves, vessels, delicate ... brain retraction. Equalized brain retraction pressure. Decreased ... Range of blade sizes from 1/4" to ... material allows preferred contour. Used in conjunction ...

The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...

Medicine Products:

Greenberg Short Retractor Arm Pattie Tray Budde Retractor Blades Budde Halo Side Rail Support